Coral Laboratories Limited (BOM:524506)

Market Cap	1.75B -34.7%
Revenue (ttm)	889.77M -19.7%
Net Income	173.53M -25.0%
EPS	48.57 -25.0%
Shares Out	3.57M
PE Ratio	10.07
Forward PE	n/a
Dividend	1.50 (0.31%)
Ex-Dividend Date	Sep 19, 2025

Volume	555
Average Volume	2,420
Open	489.30
Previous Close	489.40
Day's Range	475.00 - 489.40
52-Week Range	415.00 - 850.90
Beta	0.87
RSI	64.78
Earnings Date	Feb 13, 2026

About Coral Laboratories

Coral Laboratories Limited manufactures and sells pharmaceutical formulations in India, Ethiopia, and internationally. The company offers non-sterile products, including antibiotics/antibacterial, antifungal, gastro-intestinal drugs, antiemetic, analgesics/antipyretic/anti-inflammatory, antispasmodic, muscle relaxants, cough suppressant/expectorant, anticold, antiallergic, anti-asthmatic, cardiovascular medicines, anti-diabetic, anthelmentic, anti-protozoal/anti-amebic, antimalarial drugs, antipsychotic drugs, and thyroid products; topical, ora...

• Industry: Pharmaceutical Preparations
• Founded: 1994
• Employees: 197
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 524506

Financial Performance

In fiscal year 2025, Coral Laboratories's revenue was 1.15 billion, an increase of 37.47% compared to the previous year's 836.60 million. Earnings were 241.56 million, an increase of 52.99%.